• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Philips Awarded FDA Clearance for Digital Pathology Solution for Primary Diagnostic Use

by Jasmine Pennic 04/13/2017 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Massachusetts General Hospital Launches Digital Pathology Study

Today, Philips announced it has received regulatory clearance from the FDA (via De Novo classification) for its IntelliSite Pathology Solution, marking a significant leap forward for the pathology services industry in the U.S.  De novo classification is the regulatory pathway for marketing clearance for novel, low- to moderate-risk medical devices that are the first of their kind

As the first and only digital pathology system to be approved for primary diagnostic use in the country, today’s news has implications not only for improving laboratory workflow and efficiencies, but also for improving the quality and accuracy of cancer diagnostics through computational pathology—an approach to rendering disease diagnoses that incorporates multiple sources of data and uses mathematical models to generate clinically actionable inferences.

Philips IntelliSite Pathology Solution is an automated digital pathology image creation, viewing and management system comprised of an ultra-fast pathology slide scanner, an image management system and a display. This solution is complemented by advanced software tools to manage the scanning, storage, presentation, reviewing, and sharing of information. By supporting the transition to digital workflows, Philips seeks to help pathology laboratories simplify access to histopathology information and help staff work more efficiently.

The FDA evaluated data from a clinical study of approximately 2,000 surgical pathology cases. This was one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes. Sixteen pathologists at four clinical study sites – Cleveland Clinic, University of Virginia, Miraca Life Sciences and Advanced Pathology Associates – conducted approximately 16,000 reads across 2,000 cases. FDA’s news release ‘FDA allows marketing of first whole slide imaging system for digital pathology’ can be found here.

Pathology services are under pressure to meet the increasingly complex demands of cancer care. As the number of cancer cases continue to grow, the complexity and number of tests have simultaneously increased to support improved patient care. Pathologists must work as efficiently and effectively as possible to analyze the complex information that influences the design of personalized treatments. Outside the U.S., where CE-IVD mark has allowed primary diagnosis since 2014, digital pathology is recognized for increased efficiencies in the logistics and consultation needs in primary diagnosis of histopathology images. 

It is an exciting time in pathology as paradigm shifts are being witnessed in cancer care with precision medicine and personalized treatments increasing by the day – pathologists are absolutely central to this dream of personalized medicine.

“The clearance for Philips IntelliSite Pathology Solution marks a major milestone for innovation in pathology services in the U.S.,” said Russ Granzow, General Manager of Philips Digital Pathology Solutions. “Not only will it promote increased efficiencies and collaboration between pathologists, but it also opens a complete new dimension towards computational pathology which aims to increase accuracies and ultimately enhance patient care.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: De novo classification, FDA Clearance, IntelliSite Pathology Solution, Philips, Philips’ IntelliSite Solution

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |